Maravai LifeSciences Holdings, Inc.
MRVI
$1.77
$0.052.91%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 56.41M | 65.20M | 73.40M | 64.18M | 74.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.41M | 65.20M | 73.40M | 64.18M | 74.14M |
| Cost of Revenue | 37.44M | 36.83M | 38.27M | 38.34M | 35.11M |
| Gross Profit | 18.96M | 28.37M | 35.13M | 25.84M | 39.03M |
| SG&A Expenses | 41.24M | 39.09M | 40.56M | 40.89M | 34.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.25M | 80.26M | 84.11M | 84.25M | 74.08M |
| Operating Income | -26.84M | -15.06M | -10.71M | -20.07M | 61.00K |
| Income Before Tax | -46.50M | -175.64M | -16.93M | -22.41M | 656.19M |
| Income Tax Expenses | -7.00K | 311.00K | -2.44M | 271.00K | 766.17M |
| Earnings from Continuing Operations | -46.50M | -175.96M | -14.49M | -22.68M | -109.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 20.35M | 76.92M | 6.91M | 10.60M | 4.02M |
| Net Income | -26.15M | -99.04M | -7.59M | -12.08M | -105.96M |
| EBIT | -26.84M | -15.06M | -10.71M | -20.07M | 61.00K |
| EBITDA | -14.47M | -3.12M | 1.71M | -8.42M | 10.86M |
| EPS Basic | -0.18 | -0.70 | -0.06 | -0.09 | -0.80 |
| Normalized Basic EPS | 0.00 | 0.45 | -0.03 | -0.03 | 3.17 |
| EPS Diluted | -0.18 | -0.70 | -0.06 | -0.09 | -0.80 |
| Normalized Diluted EPS | 0.00 | 0.45 | -0.03 | -0.03 | 3.17 |
| Average Basic Shares Outstanding | 141.81M | 141.56M | 135.84M | 132.33M | 132.14M |
| Average Diluted Shares Outstanding | 141.81M | 141.56M | 135.84M | 132.33M | 132.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |